Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6861-6868

  Gerber, Jeffrey S ^a   Mosser, David M ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 1104 Microbiology Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; FC RECEPTOR; GLYCOPROTEIN GP 39; HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 12; LIPOTEICHOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; ENDOTOXEMIA; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035337139     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6861     Document Type: Article

References (57)

1. Gerber, J. G., and D. M. Mosser. 2000. Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. Microbes Infect. 3:131.
2. Hulett, M. D., and P. M. Hogarth. 1994. Molecular basis of Fc receptor function. Adv. Immunol. 57:1.
3. Daeron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15:203.
4. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
5. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 4:471.
6. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275.
7. Jouanguy, E., R. Doffinger, S. Dupuis, A. Pallier, F. Altare, and J. L. Casanova. 1999. IL-12 and IFN-γ in host defense against mycobacteria and salmonella in mice and men. Curr. Opin. Immunol. 11:346.
8. Romagnani, S. 1997. The Th1/Th2 paradigm. Immunol. Today 18:263.
9. Leonard, J. P., K. E. Waldburger, R. G. Schaub, T. Smith, A. K. Hewson, M. L. Cuzner, and S. J. Goldman. 1997. Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit. Rev. Immunol. 17:545.
10. Comabella, M., K. Balashov, S. Issazadeh, D. Smith, H. L. Weiner, and S. J. Khoury. 1998. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102:671.
11. Jun, H. S., C. S. Yoon, L. Zbytnuik, N. van Rooijen, and J. W. Yoon. 1999. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 189:347.
12. Heinzel, F. P., R. M. Rerko, P. Ling, J. Hakimi, and D. S. Schoenhaut. 1994. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of γ interferon. Infect. Immun. 62:4244.
13. Hodge-Dufour, J., P. W. Noble, M. R. Horton, C. Bao, M. Wysoka, M. D. Burdick, R. M. Strieter, G. Trinchieri, and E. Pure. 1997. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J. Immunol. 159:2492.
14. Wysocka, M., M. Kubin, L. Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25:672.
15. Mattner, F., L. Ozmen, F. J. Podlaski, V. L. Wilkinson, D. H. Presky, M. K. Gately, and G. Alber. 1997. Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor α-dependent shock. Infect. Immun. 65:4734.
16. Moore, K. W., A. O'Garra, M. R. de Waal, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165.
17. Mosmann, T. R. 1994. Properties and functions of interleukin-10. Adv. Immunol. 56:1.
18. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081.
19. De Waal, M. R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. De Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209.
20. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
21. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549.
22. Gazzinelli, R. T., I. P. Oswald, S. L. James, and A. Sher. 1992. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J. Immunol. 148:1792.
23. De Waal, M. R., J. Haanen, H. Spits, M. G. Roncarolo, V. A. Te, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. De Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of munocytes via down-regulation of class II major histocompatibility complex expression. J. Exp. Med. 174:915.
24. Willems, F., A. Marchant, J. P. Delville, C. Gerard, A. Delvaux, T. Velu, M. de Boer, and M. Goldman. 1994. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24:1007.
25. Van der, P. T., and S. J. van Deventer. 1999. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13:413.
26. Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547.
27. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205.
28. Bean, A. G., R. A. Freiberg, S. Andrade, S. Menon, and A. Zlotnik. 1993. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect. Immun. 61:4937.
29. Rogy, M. A., T. Auffenberg, N. J. Espat, R. Philip, D. Remick, G. K. Wollenberg, E. M. Copeland III, and L. L. Moldawer. 1995. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J. Exp. Med. 181:2289.
30. Kato, T., A. Murata, H. Ishida, H. Toda, N. Tanaka, H. Hayashida, M. Monden, and N. Matsuura. 1995. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob. Agents Chemother. 39:1336.
31. Ishida, H., R. Hastings, L. Thompson-Snipes, and M. Howard. 1993. Modified immunological status of anti-IL-10 treated mice. Cell. Immunol. 148:371.
32. Marchant, A., C. Bruyns, P. Vandenabeele, M. Ducarme, C. Gerard, A. Delvaux, D. De Groote, D. Abramowicz, T. Velu, and M. Goldman. 1994. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24:1167.
33. Berg, D. J., R. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, and D. Rennick. 1995. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96:2339.
34. Van der, P. T., A. Marchant, W. A. Buurman, L. Berman, C. V. Keogh, D. D. Lazarus, L. Nguyen, M. Goldman, L. L. Moldawer, and S. F. Lowry. 1995. Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 155:5397.
35. Standiford, T. J., R. M. Strieter, N. W. Lukacs, and S. L. Kunkel. 1995. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155: 2222.
36. Pajkrt, D., L. Camoglio, M. C. Tiel-van Buul, K. de Bruin, D. L. Cutler, M. B. Affrime, G. Rikken, P. T. van der, J. W. ten Cate, and S. J. van Deventer. 1997. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J. Immunol. 158:3971.
37. Olszyna, D. P., D. Pajkrt, F. N. Lauw, S. J. van Deventer, and, P. T. van der. 2000. Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J. Infect. Dis. 181:613.
38. Pajkrt, D., P. T. van der, M. Levi, D. L. Cutler, M. B. Affrime, E. A. van den, J. W. ten Cate, and S. J. van Deventer. 1997. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 89:2701.
39. Brandtzaeg, P., L. Osnes, R. Ovstebo, G. B. Joo, A. B. Westvik, and P. Kierulf. 1996. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J. Exp. Med. 184:51.
40. Sutterwala, F. S., G. J. Noel, R. Clynes, and D. M. Mosser. 1997. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185:1977.
41. Sutterwala, F. S., G. J. Noel, P. Salgame, and D. M. Mosser. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type 1. J. Exp. Med. 188:217.
42. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/ IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187:537.
43. Karp, C. L., M. Wysocka, L. M. Wahl, J. M. Ahearn, P. J. Cuomo, B. Sherry, G. Trinchieri, and D. E. Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. Science 273:228.
44. Marth, T., and B. L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185:1987.
45. D'Ambrosio, D., M. Cippitelli, M. G. Cocciolo, D. Mazzeo, P. Di Lucia, R. Lang, F. Sinigaglia, and P. Panina-Bordignon. 1998. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-κB down-regulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101:252.
46. Van der Pouw Kraan, T. C., A. Snijders, L. C. Boeije, E. R. de Groot, A. E. Alewijnse, R. Leurs, and L. A. Aarden. 1998. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J. Clin. Invest. 102:1866.
47. Wittmann, M., J. Zwirner, V. A. Larsson, K. Kirchhoff, G. Begemann, A. Kapp, O. Gotze, and T. Werfel. 1999. C5a suppresses the production of IL-12 by IFN-γ-primed and lipopolysaccharide-challenged human monocytes. J. Immunol. 162:6763.
48. Link, A. A., T. Kino, J. A. Worth, J. L. McGuire, M. L. Crane, G. P. Chrousos, R. L. Wilder, and I. J. Elenkov. 2000. Ligand activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J. Immunol. 164:436.
49. Braun, M. C., E. Lahey, and B. L. Kelsall. 2000. Selective suppression of IL-12 production by chemoattractants. J. Immunol. 164:3009.
50. Means, T. K., D. T. Golenbock, and M. J. Fenton. 2000. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 11:219.
51. Van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukocyte Biol. 67:2.
52. Yoshida, Y., K. Kang, M. Berger, G. Chen, A. C. Gilliam, A. Moser, L. Wu, C. Hammerberg, and K. D. Cooper. 1998. Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin. J. Immunol. 161:5873.
53. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
54. Wanidworanun, C., and W. Strober. 1993. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J. Immunol. 151:6853.
55. Reid, R. R., A. P. Prodeus, W. Khan, T. Hsu, F. S. Rosen, and M. C. Carroll. 1997. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159:970.
56. Hellman, J., and H. S. Warren. 1999. Antiendotoxin strategies. Infect. Dis. Clin. North Am. 13:371.
57. Opal, S. M., and A. S. Cross. 1999. Clinical trials for severe sepsis: past failures, and future hopes. Infect. Dis. Clin. North Am. 13:285.